CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022

Rhea-AI Summary

CASI Pharmaceuticals (Nasdaq: CASI) announced a conference call scheduled for March 28, 2022, at 8:00 a.m. EDT, to review its financial results for Q4 and the year ended December 31, 2021. The call will be led by the Company's Chairman & CEO, who will discuss business updates and upcoming milestones. Investors can access the call via a local and international dialing system, with a replay option available afterward.

CASI focuses on developing innovative therapeutics in hematology and oncology, primarily targeting the greater China market.

Positive

• Focus on innovative therapeutics in hematology and oncology.
• Plans to leverage China-based regulatory competencies for market leadership.

Negative

• None.

ROCKVILLE, Md. and BEIJING, March 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the fourth quarter and for the year ended December 31^st, 2021, at 8:00 a.m. EDT on Monday, March 28^th, 2022.

On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by dialing 1-877-870-4263 (U.S.) or 1-412-317-0790 (international) and ask to be joined into the CASI Pharmaceuticals call to listen to the live conference call.

This call will be recorded and available for replay by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (international) and enter 4990100 to access the replay.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT: Rui Zhang CASI Pharmaceuticals, Inc. 240.864.2643 ir@casipharmaceuticals.com

INVESTOR CONTACT: Xuan Yang Solebury Trout 646.378.2975 xyang@soleburytrout.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-report-fourth-quarter-and-year-end-2021-financial-results-and-host-conference-call-march-28-2022-301508675.html

SOURCE CASI Pharmaceuticals, Inc.

FAQ

When will CASI Pharmaceuticals report its financial results?

CASI Pharmaceuticals will report its financial results for the fourth quarter and the year ended December 31, 2021, on March 28, 2022.

What time is the CASI Pharmaceuticals conference call?

The conference call will take place at 8:00 a.m. EDT on March 28, 2022.

How can I access the CASI Pharmaceuticals conference call?

The conference call can be accessed by dialing 1-877-870-4263 (U.S.) or 1-412-317-0790 (international).

What topics will be discussed during the CASI Pharmaceuticals conference call?

The call will include financial results, business updates, and upcoming milestones.